Raltitrexed plus levofolinic acid and bolus/continuous infusion 5-fluorouracil on a biweekly schedule for elderly patients with advanced colorectal carcinomas

Annals of Oncology

Volumn 17, Issue SUPPL. 7, 2006, Pages

  Gebbia, Vittorio ^a,l   Verderame, F ^b   Ferrau F ^c   Bordonaro, R ^d   Callari, A ^e   Caruso, M ^f   Tirrito, M L ^g   Valenza, R ^h   Cicero, G ⁱ   Borsellino, N ^j   Tralongo, P ^k  

^a UNIVERSITY OF PALERMO   (Italy)

^b Ospedale Civile   (Italy)

^c Ospedale San Vincenzo   (Italy)

^d UNIVERSITY OF CATANIA   (Italy)

^e Casa di Cura Noto Pasqualino   (Italy)

^f Medical Oncology Unit   (Italy)

^g Casa di Cura Torina   (Italy)

^h Osp Vittorio Emanuele III   (Italy)

ⁱ Castrovillari Hospital   (Italy)

^j Buccheri La Ferla Hospital   (Italy)

^k Ospedale Di Maria   (Italy)

^l NONE   (Italy)

more..

Author keywords

5 fluorouracil; Colorectal cancer; Folinic acid; Metastases; Raltitrexed

Indexed keywords

ANTINEOPLASTIC AGENT; DEXAMETHASONE; FLUOROURACIL; IRINOTECAN; LEVOFOLINIC ACID; RALTITREXED; SEROTONIN 3 ANTAGONIST; UNCLASSIFIED DRUG;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADVANCED CANCER; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; BOLUS INJECTION; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLON SURGERY; COLORECTAL CARCINOMA; CONFIDENCE INTERVAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ELDERLY CARE; ERYTHROCYTE TRANSFUSION; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL TIME; THROMBOCYTOPENIA; TUMOR GROWTH;

EID: 33745614639     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl953     Document Type: Article

References (28)

1. Landis SH, Taylor M, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin 1998; 48: 6-29.
2. Kohne CH, Grothey A, Bokemeyer C et al. Chemotherapy in elderly patients with colorectal cancer. Ann Oncol 2001 12: 435-442.
3. Jansman FG, Sleijfer DT, Coenen JL et al. Risk factors determining chemotherapeutic toxicity in patients with advanced colorectal cancer, Drug Saf 2000; 23: 255-278.
4. Meta-Analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998; 6: 301-308.
5. Bertino GR. Chemotherapy of colorectal cancer: History and new themes. Semin Oncol 1997; 24 (Suppl 18): S18-37.
6. Saltz L, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343: 905-914.
7. Douillard JV, Cunningham D, Roth A et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicenter randomised trial. Lancet 2000; 355: 1041-1047.
8. De Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947.
9. Giacchetti S, Zidani R, Perpoint B et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18: 136-147.
10. Colucci G, Gebbia V, Paoletti G et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: A multicenter study of the Gruppo Oncologico dell'Italia Meridionale. J Clin Oncol 2005; 23: 4866-4875.
11. Van Cutsem E. Raltitrexed (Tomudex) in combination treatment for colorectal cancer: New perspectives. Eur J Cancer 1999; 35 (Suppl 1): S1-S5.
12. Kempin S, Gutierez J, Wilson E et al. Raltitrexed (Tomudex): An alternative choice in patients intolerant to 5-fluorouracil. Cancer Invest 2002; 20: 992-995.
13. Farruggia DC, Ford HE, Cunningham D et al. Thymidylate synthase expression in advanced colorectal cancer predicts for response to raltitrexed. Clin Cancer Res 2003; 9: 792-801.
14. Zalcberg JR, Cunningham D, Van Cutsem E et al. ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. Tomudex Colorectal Study Group. J Clin Oncol 1996; 14: 716-721.
15. Feliu J, Castanon C, Salud A et al. Phase II randomised trial of raltitrexed-oxaliplatin vs raltitrexed-irinotecan as first-line treatment in advanced colorectal cancer. Br J Cancer 2005; 93: 1230-1235.
16. Vincent M, Ho C, Tomiak A et al. Toxicity analysis of the 5-day bolus 5-fluorouracil/folinic acid regimen for the treatment of colorectal carcinoma from 2 randomized controlled trials: A concern about dose. Clin Colorectal Cancer 2002; 2: 111-118.
17. Kano Y, Akutsu M, Suzuki K et al. Schedule-dependent interaction between raltitrexed and 5-fluorouracil in human colon cancer cell lines in vitro. Oncol Res 2000; 12: 137-148.
18. Van Cutsem E, Cunningham D, Maroun J et al. Raltitrexed: Current clinical status and future directions. Ann Oncol 2002; 13: 513-522.
19. Schwartz GK, Bertino J, Kemeny N et al. Phase I trial of sequential raltitrexed followed by bolus 5-fluorouracil in patients with advanced colorectal cancer. Anticancer Drugs 2004; 15: 219-227.
20. Caponigro F Avallone A, Budillon A et al. Raltitrexed/ 5-fluorouracil-based combination chemotherapy regimens in anticancer therapy. Anticancer Drugs 2001; 12: 489-497.
21. Sprangers MA. Quality-of-life assessment in colorectal cancer patients: evaluation of cancer therapies. Semin Oncol 1999; 26: 691-696.
22. Feliu J, Mel JR, Camps C et al. Raltitrexed in the treatment of elderly patients with advanced colorectal cancer: An active and low toxicity regimen. Eur J Cancer 2002; 38: 1204-1211.
23. Cunningham D, Zalcberg J, Maroun J et al. Efficacy, tolerability and management of raltitrexed (Tomudex) monatherapy in patients with advanced colorectal cancer. A review of phase II/III trials. Eur J Cancer 2002; 38: 478-486.
24. Franchi F, Pastore C, Caporale A et al. Favorable toxicity profile of raltitrexed in elderly patients treated for colorectal cancer: A case series. Gerontology 2003; 49: 324-327.
25. Schwarzt GK, Harstrick A, Gonzalez Baron M. Raltitrexed (Tomudex) in combination with 5-fluorouracil for the treatment of patients with advanced colorectal cancer: Preliminary results from phase I clinical trials. Eur J Cancer 1999; 35 (Suppl 1): S9-S13.
26. Schwartz GK, Bertino J, Kemeny N et al. Phase I trial of sequential raltitrexed followed by bolus 5-fluorouracil in patients with advanced colorectal cancer. Anticancer Drugs 2004; 15: 219-222.
27. Caponigro F, Avallone A, Mc Leod H et al. Phase I and pharmacokinetic study of tomudex combined with 5-fluorouracil plus levofolinic acid in advanced head and neck cancer and colorectal cancer. Clin Cancer Res 1999; 5: 3948-3955.
28. Comella P, De Vita F, Mancarella S et al. Biweekly irinotecan or raltitrexed plus 6S-leucovorin and bolus 5-fluorouracil in advanced colorectal carcinoma: A Southern Italy Cooperative Oncology Group phase II-III randomized trial. Ann Oncol 2000; 11: 1323-1333.